

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKAB1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB 10	COMPENDEX reloaded and enhanced
NEWS	15	FEB 11	WTEXTILES reloaded and enhanced
NEWS	16	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS	24	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS	25	MAR 11	ESBIOBASE reloaded and enhanced
NEWS	26	MAR 20	CAS databases on STN enhanced with new super role

for nanomaterial substances
 NEWS 27 MAR 23 CA/CAPLUS enhanced with more than 250,000 patent
 equivalents from China
 NEWS 28 MAR 30 IMSPATENTS reloaded and enhanced
 NEWS 29 APR 03 CAS coverage of exemplified prophetic substances
 enhanced

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
 AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN Welcome Banner and News Items
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
 specific topic.

All use of STN is subject to the provisions of the STN customer
 agreement. This agreement limits use to scientific research. Use
 for software development or design, implementation of commercial
 gateways, or use of CAS and STN data in the building of commercial
 products is prohibited and may result in loss of user privileges
 and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 08:51:07 ON 06 APR 2009

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 08:51:15 ON 06 APR 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 5 APR 2009 HIGHEST RN 1132636-28-2
 DICTIONARY FILE UPDATES: 5 APR 2009 HIGHEST RN 1132636-28-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.



Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10551737 elected April 6.str



```

chain nodes :
10 11 12 18 19 20 22
ring nodes :
1 2 3 4 5 6 13 14 15 16 17
chain bonds :
3-11 4-10 10-22 11-12 15-18 16-22 18-19 18-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-17 14-15 15-16 16-17
exact/norm bonds :
3-11 4-10 10-22 11-12 15-16 16-17 16-22 18-19 18-20
exact bonds :
13-14 13-17 14-15 15-18
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 13 :

G1:O,S

G2:Cb,Cy,Hy

G3:C,O,S

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 10:CLASS 11:CLASS 12:CLASS
13:Atom
14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS 20:CLASS 22:CLASS

```

L1 STRUCTURE UPLOADED

=> d L1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.48	0.70

FILE 'CAPLUS' ENTERED AT 08:51:30 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Apr 2009 VOL 150 ISS 15
FILE LAST UPDATED: 5 Apr 2009 (20090405/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L1 SSS full
REGISTRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 08:51:34 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 320569 TO ITERATE

100.0% PROCESSED 320569 ITERATIONS 66 ANSWERS
SEARCH TIME: 00.00.13

L2 66 SEA SSS FUL L1

L3 5 L2

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:1093266 CAPLUS Full-text

DOCUMENT NUMBER: 145:432223
 TITLE: Method of treating schizophrenia prodrome
 INVENTOR(S): Woods, Scott W.
 PATENT ASSIGNEE(S): Yale University, USA
 SOURCE: PCT Int. Appl., 64pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006110724	A2	20061019	WO 2006-US13444	20060411
WO 2006110724	A3	20070322		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2006235400	A1	20061019	AU 2006-235400	20060411
CA 2602626	A1	20061019	CA 2006-2602626	20060411
EP 1871165	A2	20080102	EP 2006-740849	20060411
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2008535864	T	20080904	JP 2008-505637	20060411
PRIORITY APPLN. INFO.:			US 2005-670600P	P 20050411
			WO 2006-US13444	W 20060411

OTHER SOURCE(S): MARPAT 145:432223

AB The present invention relates to a method of treating schizophrenia prodrome in human subjects using a NMDA glycine site agonist, a glycine transporter-1 inhibitor or mixts. thereof, optionally in combination with a pharmaceutically acceptable additive, carrier or excipient.

IT 791642-83-6


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method of treating schizophrenia prodrome with NMDA glycine agonist and glycine transporter-1 inhibitor)

RN 791642-83-6 CAPLUS


CN L-Proline, 1-[2-[2-[[4-(1,1-dimethylethyl)phenyl]thio]phenoxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2009 ACS on SIN
 ACCESSION NUMBER: 2006:625349 CAPLUS [Full-text](#)
 DOCUMENT NUMBER: 145:224321
 TITLE: The synthesis and SAR of 2-arylsulfanyphenyl-1-oxyalkylamino acids as GlyT-1 inhibitors
 AUTHOR(S): Smith, Garrick; Mikkelsen, Gitte; Eskildsen, Jorgen; Bundgaard, Christoffer
 CORPORATE SOURCE: Medicinal Chemistry Research, H. Lundbeck A/S, Valby, DK 2500, Den.
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(15), 3981-3984
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 145:224321
 GI



AB Elevation of glycine levels by inhibition of the glycine transporter-1 (GlyT-1) and activation of the NMDA receptor is a potential strategy for the treatment of schizophrenia. A novel series of 2-arylsulfanyphenyl-1-oxyalkyl amino acids have been identified. The most prominent member of this series (I) is a potent GlyT-1 inhibitor (IC50 = 59 nM). In vitro and in vivo assessment of CNS exposure indicates this compound is a likely substrate for active efflux transporters.


IT 791644-20-7P 791644-21-8P
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and SAR of arylsulfanylphenyloxyalkylamino acids as GlyT-1 inhibitors)

RN 791644-20-7 CAPLUS

CN L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio][1,1'-biphenyl]-4-yl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-21-8 CAPLUS

CN L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio]-4'-methoxy[1,1'-biphenyl]-4-yl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 791642-87-0P 791644-17-2P 791644-19-3P

794510-03-5P 905815-62-5P 905815-63-6P

905815-64-7P 905815-65-8P 905815-66-3P

905815-67-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and SAR of arylsulfanylphenyloxyalkylamino acids as GlyT-1 inhibitors)

RN 791642-87-0 CAPLUS

CN L-Proline, 1-[2-[2-[(3-chlorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-17-2 CAPLUS

CN L-Proline, 1-[2-[3-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA
INDEX NAME)


Absolute stereochemistry.



RN 791644-18-3 CAPLUS

CN L-Proline, 1-[2-[5-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA
INDEX NAME)


Absolute stereochemistry.



RN 794510-03-5 CAPLUS

CN L-Proline, 1-[2-[4-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA
INDEX NAME)


Absolute stereochemistry.



RN 905815-62-5 CAPLUS

CN D-Proline, 1-[2-[2-[(3-chlorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 905815-63-6 CAPLUS

CN L-Proline, 1-[2-[2-chloro-6-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 905815-64-7 CAPLUS

CN L-Proline, 1-[2-[[4-[(3-fluorophenyl)thio][1,1'-biphenyl]-3-yl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 905815-65-8 CAPLUS

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(3-thienyl)phenoxy]ethyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 905815-66-9 CAPLUS

CN L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio]-3'-methoxy[1,1'-biphenyl]-4-yl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 905815-67-0 CAPLUS


CN L-Proline, 1-[2-[[4'-chloro-3-[(3-fluorophenyl)thio][1,1'-biphenyl]-4-yl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 791642-79-0P 791644-01-4P 905816-02-6P
 905816-03-7P 905816-06-0P 905816-07-1P
 905816-08-2P 905816-09-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (synthesis and SAR of arylsulfanylphenoxyalkylamino acids as GlyT-1
 inhibitors)
 RN 791642-79-0 CAPLUS
 CN L-Proline, 1-[2-[4-bromo-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 791644-01-4 CAPLUS
 CN L-Proline, 1-[2-[5-bromo-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
 1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 905816-02-6 CAPLUS

CN D-Proline, 1-[2-[2-[(3-chlorophenyl)thio]phenoxy]ethyl]-,
1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 905816-03-7 CAPLUS

CN L-Proline, 1-[2-[2-[(3-chlorophenyl)thio]phenoxy]ethyl]-,
1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 905816-06-0 CAPLUS

CN L-Proline, 1-[2-[5-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 905816-07-1 CAPLUS

CN L-Proline, 1-[2-[2-chloro-6-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 905816-08-2 CAPLUS

CN L-Proline, 1-[2-[3-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
1,1-dimethylethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 905816-09-3 CAPLUS

CN L-Proline, 1-[2-[4-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2009 ACS on SIN

ACCESSION NUMBER: 2004:965214 CAPLUS Full-text

DOCUMENT NUMBER: 141:411217

TITLE: A preparation of oxyphenyl and sulfanylphenyl derivatives of amino acids, useful as glycine transporter inhibitors

INVENTOR(S): Smith, Garrick Paul; Mikkelsen, Gitte; Andersen, Kim; Greve, Daniel Rodriguez; Eskildsen, Joergen

PATENT ASSIGNEE(S): H. Lundbeck A/S, Den.

SOURCE: PCT Int. Appl., 87 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096761	A1	20041111	WO 2004-DK290	20040427
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004233942	A1	20041111	AU 2004-233942	20040427
CA 2523585	A1	20041111	CA 2004-2523585	20040427
EP 1622868	A1	20060208	EP 2004-729612	20040427
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009739	A	20060509	BR 2004-9739	20040427
JP 2006524642	T	20061102	JP 2006-504368	20040427
MX 2005011198	A	20051214	MX 2005-11198	20051018
IN 2005CN02812	A	20070525	IN 2005-CN2812	20051031
NO 2005005632	A	20051129	NO 2005-5632	20051129
US 20060235003	A1	20061019	US 2006-551737	20060606
PRIORITY APPLN. INFO.:			DK 2003-649	A 20030430
			US 2003-466755P	P 20030430

OTHER SOURCE(S):

MARPAT 141:411217

GI



AB The invention relates to a preparation of aromatic oxyphenyl and aromatic sulfanyphenyl derivs. of formula I [wherein: X is O, S, or CH₂, etc.; Y is O or S; R₁, R₂, R₃, and R₄ are independently selected from H, halogen, CN, NO₂, or alk(en/yn)yl, etc.; R₅ is (un)substituted aryl or monocyclic heteroaryl; R₆ is H, alk(en/yn)yl, cycloalk(en)yl, or alk(en/yn)ylsulfanyl, etc.; R₇ and R₈ are independently selected from H, alk(en/yn)yl, or cycloalk(en)yl; R₉ and R₁₁ are independently selected from H, alk(en/yn)yl, hydroxyalk(en/yn)yl, or alk(en/yn)ylsulfanyl, etc.; R₁₀ is H, alk(en/yn)yl, aryl, or arylalk(en/yn)yl, etc.; R₆ and R₈ together with the nitrogen may form 3-7 membered heterocyclic ring], useful as glycine transporter inhibitors (IC₅₀ < 10000 nM). The compds. of formula I are useful for the treatment of diseases such as schizophrenia, including both the pos. and the neg. symptoms of schizophrenia. For instance, pyrrolidinecarboxylic acid derivative II was prepared via etherification of 2-(3-fluorophenylsulfanyl)phenol by (hydroxyethyl)pyrrolidinecarboxylate derivative III.


IT 791642-79-0P, (S)-1-[2-[4-Bromo-2-(3-fluorophenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid tert-butyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of oxyphenyl and sulfanyphenyl derivs. of amino acids, useful as glycine transporter inhibitors)

RN 791642-79-0 CAPLUS

CN L-Proline, 1-[2-[4-bromo-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 791642-81-4P, (S)-1-[2-[2-(4-Fluorophenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid
 791642-83-6P, (S)-1-[2-[2-(4-tert-Butylphenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid
 791642-84-7P, (S)-1-[2-[2-(4-Trifluoromethylphenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid
 791642-85-8P, (S)-1-[2-[2-(3-Fluorophenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid
 791642-86-9P, (S)-1-[2-[2-(4-Chlorophenylsulfanyl)-phenoxy]-ethyl]pyrrolidine-2-carboxylic acid 791642-87-0P,
 (S)-1-[2-[2-(3-Chlorophenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid 791642-88-1P, (S)-1-[2-[2-(3,4-Dichlorophenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid
 791642-90-5P, (S)-1-[2-[2-(3-Chloro-4-fluorophenylsulfanyl)phenoxy]ethyl]pyrrolidine-2-carboxylic acid
 791642-91-6P, (S)-1-[2-[2-(3-Chlorophenoxy)phenoxy]ethyl]pyrrolidine-2-carboxylic acid
 791642-92-7P 791642-93-8P 791642-94-9P
 791642-95-0P 791642-97-2P 791642-98-3P
 791642-99-4P 791643-00-0P 791643-01-1P
 791643-85-1P 791643-88-4P 791643-90-8P
 791643-91-9P 791643-92-0P 791643-94-2P
 791643-95-3P 791643-97-5P 791643-99-7P
 791644-00-3P 791644-02-5P 791644-04-7P
 791644-06-9P 791644-08-1P 791644-09-2P
 791644-15-0P 791644-17-2P 791644-18-3P
 791644-19-4P 791644-20-7P 791644-21-8P
 791644-22-9P 791644-23-0P 791644-24-1P
 791644-25-2P 791644-26-3P 791644-27-4P
 791644-28-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of oxyphenyl and sulfanylphenyl derivs. of amino acids, useful as glycine transporter inhibitors)

RN 791642-81-4 CAPLUS

CN L-Proline, 1-[2-[2-[(4-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-83-6 CAPLUS

CN L-Proline, 1-[2-[2-[[4-(1,1-dimethylethyl)phenyl]thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-84-7 CAPLUS

CN L-Proline, 1-[2-[2-[[4-(trifluoromethyl)phenyl]thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-85-8 CAPLUS

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-86-9 CAPLUS

CN L-Proline, 1-[2-[2-[(4-chlorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-87-0 CAPLUS

CN L-Proline, 1-[2-[2-[(3-chlorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-88-1 CAPLUS

CN L-Proline, 1-[2-[2-[(3,4-dichlorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-90-5 CAPLUS

CN L-Proline, 1-[2-[2-[(3-chloro-4-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-91-6 CAPLUS

CN L-Proline, 1-[2-[2-(3-chlorophenoxy)phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-92-7 CAPLUS

CN L-Proline, 1-[2-[2-(4-chlorophenoxy)phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-93-8 CAPLUS

CN L-Proline, 1-[2-[2-(4-methoxyphenoxy)phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-94-9 CAPLUS

CN L-Proline, 1-[2-[2-(3,4-difluorophenoxy)phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-95-0 CAPLUS

CN L-Proline, 1-[2-[2-(4-chlorophenoxy)phenoxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-97-2 CAPLUS

CN L-Proline, 1-[2-[2-(3,4-difluorophenoxy)phenoxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-98-3 CAPLUS

CN L-Proline, 1-[2-[2-(3-fluorophenoxy)phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791642-99-4 CAPLUS

CN L-Proline, 1-[2-[2-(3-fluorophenoxy)phenoxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791643-00-0 CAPLUS

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]phenoxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791643-01-1 CAPLUS

CN L-Proline, 1-[2-[2-[(3-chlorophenyl)thio]phenoxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791643-85-1 CAPLUS

CN L-Proline, 1-[3-[2-[(3-fluorophenyl)thio]phenyl]propyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791643-88-4 CAPLUS

CN L-Proline, 1-[2-[4-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791643-90-8 CAPLUS

CN L-Proline, 1-[2-[3-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791643-91-9 CAPLUS

CN L-Proline, 1-[2-[5-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791643-92-0 CAPLUS

CN L-Proline, 1-[2-[4-cyano-2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791643-94-2 CAPLUS

CN L-Proline, 1-[2-[5-chloro-2-(phenylthio)phenoxy]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791643-95-3 CAPLUS

CN L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio][1,1'-biphenyl]-4-yl]oxy]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791643-97-5 CAPLUS

CN L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio]-4'-methoxy[1,1'-biphenyl]-4-yl]oxy]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791643-99-7 CAPLUS

CN L-Proline, 1-[2-[[4'-cyano-3-[(3-fluorophenyl)thio][1,1'-biphenyl]-4-yl]oxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791644-00-3 CAPLUS

CN L-Proline, 1-[2-[[4'-cyano-4-[(3-fluorophenyl)thio][1,1'-biphenyl]-3-yl]oxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-02-5 CAPLUS

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-5-(3-thienyl)phenoxy]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-04-7 CAPLUS

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(5-pyrimidinyl)phenoxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791644-06-9 CAPLUS

CN L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio]-3'-(methanesulfonyl)[1,1'-biphenyl]-4-yl]oxy]ethyl]-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791644-08-1 CAPLUS

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(4-morpholinyl)phenoxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791644-09-2 CAPLUS

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(1-piperidinyl)phenoxy]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791644-15-0 CAPLUS

CN L-Proline, 1-[3-[2-[(3-fluorophenyl)thio]phenyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-17-2 CAPLUS

CN L-Proline, 1-[2-[3-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-18-3 CAPLUS

CN L-Proline, 1-[2-[5-chloro-2-[(3-fluorophenyl)thio]phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-19-4 CAPLUS

CN L-Proline, 1-[2-[5-chloro-2-(phenylthio)phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-20-7 CAPLUS

CN L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio][1,1'-biphenyl]-4-yl]oxy]ethyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 791644-21-8 CAPLUS

CN L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio]-4'-methoxy[1,1'-biphenyl]-4-yl]oxy]ethyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 791644-22-9 CAPLUS

CN L-Proline, 1-[2-[[4'-cyano-3-[(3-fluorophenyl)thio][1,1'-biphenyl]-4-yl]oxy]ethyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 791644-23-0 CAPLUS

CN L-Proline, 1-[2-[[4'-cyano-4-[(3-fluorophenyl)thio][1,1'-biphenyl]-3-yl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-24-1 CAPLUS

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-5-(3-thienyl)phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-25-2 CAPLUS

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(5-pyrimidinyl)phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-26-3 CAPLUS

CN L-Proline, 1-[2-[[3-[(3-fluorophenyl)thio]-3'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-27-4 CAPLUS

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(4-morpholinyl)phenoxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 791644-28-5 CAPLUS

CN L-Proline, 1-[2-[2-[(3-fluorophenyl)thio]-4-(1-piperidinyl)phenoxy]ethyl]-
(CA INDEX NAME)

Absolute stereochemistry.




IT 791643-98-6 791644-01-4 791644-07-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of oxyphenyl and sulfanylphenyl derivs. of amino
acids, useful as glycine transporter inhibitors)

RN 791643-98-6 CAPLUS

CN L-Proline, 1-[2-[4-bromo-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 791644-01-4 CAPLUS


CN L-Proline, 1-[2-[5-bromo-2-[(3-fluorophenyl)thio]phenoxy]ethyl]-,
1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 791644-07-0 CAPLUS
 CN L-Proline, 1-[2-[4-bromo-2-((3-fluorophenyl)thio)phenoxy]ethyl]-, butyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:666715 CAPLUS Full-text

DOCUMENT NUMBER: 133:252449

TITLE: Quinazolines and other bicyclic heterocycles, pharmaceutical compositions containing these compounds as tyrosine kinase inhibitors, and processes for preparing them

INVENTOR(S): Himmelsbach, Frank; Langkopf, Elke; Blech, Stefan;

PATENT ASSIGNEE(S): Jung, Birgit; Metz, Thomas; Solca, Flavio

SOURCE: Boehringer Ingelheim Pharma K.-G., Germany

PCT Int. Appl., 153 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000055141	A1	20000921	WO 2000-EP2228	20000314
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				

MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

DE 19911509 A1 20000921 DE 1999-19911509 19990315
 CA 2368059 A1 20000921 CA 2000-2368059 20000314
 EP 1163227 A1 20011219 EP 2000-909360 20000314
 EP 1163227 B1 20050928

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO


BR 2000009076 A 20011226 BR 2000-9076 20000314
 TR 200102782 T2 20020422 TR 2001-2782 20000314
 JP 2002539199 T 20021119 JP 2000-605571 20000314
 JP 3754617 B2 20060315
 EE 200100484 A 20021216 EE 2001-484 20000314
 EE 5034 B1 20080616
 HU 2002001832 A2 20021228 HU 2002-1832 20000314
 HU 2002001832 A3 20030228
 NZ 514706 A 20031128 NZ 2000-514706 20000314
 AU 772520 B2 20040429 AU 2000-31667 20000314
 CN 1150171 C 20040519 CN 2000-805005 20000314
 AT 305456 T 20051015 AT 2000-909360 20000314
 ES 2250111 T3 20060416 ES 2000-909360 20000314
 IL 144626 A 20070211 IL 2000-144626 20000314
 TW 268924 B 20061221 TW 2000-89104508 20000426
 IN 2001MN00956 A 20050304 IN 2001-MN956 20010809
 MX 2001008324 A 20020311 MX 2001-8324 20010816
 US 20020177601 A1 20021128 US 2001-938235 20010823
 ZA 2001007185 A 20020621 ZA 2001-7185 20010830
 BG 105893 A 20020531 BG 2001-105893 20010912
 BG 65130 B1 20070330
 KR 749292 B1 20070814 KR 2001-711645 20010913
 NO 2001004487 A 20010914 NO 2001-4487 20010914
 HK 1043124 A1 20041203 HK 2002-104697 20020625
 JP 2006077010 A 20060323 JP 2005-259571 20050907
 US 20060063752 A1 20060323 US 2005-266920 20051104

PRIORITY APPLN. INFO.:

DE 1999-19911509 A 19990315
 JP 2000-605571 A3 20000314
 WO 2000-EP2228 W 20000314
 US 2001-938235 A1 20010823

OTHER SOURCE(S): MARPAT 133:252449

GI




AB The invention relates to bicyclic heterocyclic compounds. I [R1 = H, alkyl; R2 = (un)substituted Ph, CH2Ph, or CH(Me)Ph; R3, R4 = H, F, Cl, OMe, or Me optionally substituted by OMe, NMe2, NET2, pyrrolidino, piperidino, or morpholino; X = N or C(CN); A = O, NH, (un)substituted alkylene, O-alkylene, NH-alkylene, O-cycloalkylene, etc.; B = (un)substituted amine-containing sidechain, piperazino, alkyleneimino, morpholino, etc.; or AB = H, F, Cl, alkoxy, amino, etc.; C = groups similar to A; D = groups similar to B; with a variety of provisos] and their tautomers, stereoisomers, and salts, and particularly their physiologically acceptable salts with inorganic or organic acids or bases. The compounds have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, and are useful in treating diseases, particularly tumor diseases, and diseases of the lung and airways. Over 20 compounds were prepared, and over 200 are listed. For instance, alkylation of 4-(3-chloro-4-fluorophenylamino)-6-[3-(1-piperazinyl)propyloxy]-7-methoxyquinazoline (preparation given) by Me bromoacetate gave 51% title compound II. The latter compound inhibited EGF-dependent proliferation of F/L-HER2 cells in vitro, with an IC50 of 46 nM.

IT 295330-27-7P, (R)-4-[(3-Chloro-4-fluorophenyl)amino]-6-[2-[2-(methoxycarbonyl)pyrrolidin-1-yl]ethoxy]-7-cyclopentylxyquinazoline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of quinazoline derivs. and other bicyclic heterocycles as tyrosine kinase inhibitors)

RN 295330-27-7 CAPLUS

CN D-Proline, 1-[2-[[4-[(3-chloro-4-fluorophenyl)amino]-7-(cyclopentyl)oxy]-6-quinazolinyl]oxy]ethyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2009 ACS on SIN

ACCESSION NUMBER: 1973:64458 CAPLUS Full-text

DOCUMENT NUMBER: 78:64458

ORIGINAL REFERENCE NO.: 78:10181a,10184a

TITLE: Detection of alkali metal ions by optical rotatory dispersion. Sensitive test for sodium in the presence of lithium and potassium

AUTHOR(S): Wudl, Fred

CORPORATE SOURCE: Dep. Chem., State Univ. N. Y., Buffalo, NY, USA

SOURCE: Journal of the Chemical Society, Chemical

Communications (1972), (22), 1229-30

CODEN: JCCCAT; ISSN: 0022-4936

DOCUMENT TYPE: Journal

LANGUAGE: English

GI For diagram(s), see printed CA Issue.


AB The ORD curves of the chiral semicrown complexes (I, M = H, Li, Na, K) depend on the cation (M) and, as the interaction of I its strongest with Na, a spectropolarimetric determination of Na in the presence of Li and K is applicable.

IT 40418-12-0P

RL: PREP (Preparation)
(preparation of)

RN 40418-12-0 CAPLUS

CN Proline, 1-[[2-[(tetrahydro-2H-pyran-2-yl)oxy]phenoxy]acetyl]-, methyl ester (9CI) (CA INDEX NAME)



=> log off

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

STN INTERNATIONAL LOGOFF AT 08:52:06 ON 06 APR 2009